SLSSELLAS Life Sciences Group, Inc.
Pharmaceutical Preparations
- Revenue
- —
- Operating margin
- —
- EBITDA
- −$28M
- 10% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- −$138M net debt
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCClear—Over 10% of revenue
- Payouts exceed cash flowClear-14% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear1% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $8M | $1M | $0 | — | — | |
| Operating income | −$25M | −$42M | −$38M | −$32M | −$28M | 10% |
| Net income | −$21M | −$41M | −$37M | −$31M | −$27M | 13% |
| Operating cash flow | −$26M | −$24M | −$31M | −$35M | −$28M | 20% |
| Stock-based comp | $1M | $2M | $2M | $2M | $2M | 25% |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $2M | $4M | 160 | — |
| FY2024 | $1M | $1M | 44 | — |
| FY2023 | $2M | $801K | 45 | — |